The effect of dopamine agonist therapy on large functionless pituitary tumours.
Fifteen patients (12 male) with large pituitary tumours and serum prolactin levels below 1000 mU/l were given dopamine agonist therapy (bromocriptine, mesulergine or pergolide) for a mean of 9 months (range 3-36 months). Serum prolactin became undetectable in all. Despite this, significant suprasell...
| Автори: | , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
1985
|
| _version_ | 1826264699585429504 |
|---|---|
| author | Grossman, A Ross, R Charlesworth, M Adams, C Wass, J Doniach, I Besser, G |
| author_facet | Grossman, A Ross, R Charlesworth, M Adams, C Wass, J Doniach, I Besser, G |
| author_sort | Grossman, A |
| collection | OXFORD |
| description | Fifteen patients (12 male) with large pituitary tumours and serum prolactin levels below 1000 mU/l were given dopamine agonist therapy (bromocriptine, mesulergine or pergolide) for a mean of 9 months (range 3-36 months). Serum prolactin became undetectable in all. Despite this, significant suprasellar extensions and any associated neurological defect remained in 14 patients, who therefore were referred for surgery. In one patient there was evidence of spontaneous pituitary infarction unrelated to dopamine agonist therapy. At operation 12 patients had apparently functionless pituitary adenomas which failed to immunostain for prolactin, one had an epidermoid cyst and one a Rathke's pouch cyst. We conclude that patients with large pituitary tumours and only a mildly elevated serum prolactin are unlikely to have prolactinomas, and that such tumours are not likely to show significant tumour shrinkage with medical treatment with dopamine agonists. |
| first_indexed | 2024-03-06T20:12:03Z |
| format | Journal article |
| id | oxford-uuid:2ae6f0ac-ef62-447c-9a10-778a834526c9 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:12:03Z |
| publishDate | 1985 |
| record_format | dspace |
| spelling | oxford-uuid:2ae6f0ac-ef62-447c-9a10-778a834526c92022-03-26T12:27:49ZThe effect of dopamine agonist therapy on large functionless pituitary tumours.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2ae6f0ac-ef62-447c-9a10-778a834526c9EnglishSymplectic Elements at Oxford1985Grossman, ARoss, RCharlesworth, MAdams, CWass, JDoniach, IBesser, GFifteen patients (12 male) with large pituitary tumours and serum prolactin levels below 1000 mU/l were given dopamine agonist therapy (bromocriptine, mesulergine or pergolide) for a mean of 9 months (range 3-36 months). Serum prolactin became undetectable in all. Despite this, significant suprasellar extensions and any associated neurological defect remained in 14 patients, who therefore were referred for surgery. In one patient there was evidence of spontaneous pituitary infarction unrelated to dopamine agonist therapy. At operation 12 patients had apparently functionless pituitary adenomas which failed to immunostain for prolactin, one had an epidermoid cyst and one a Rathke's pouch cyst. We conclude that patients with large pituitary tumours and only a mildly elevated serum prolactin are unlikely to have prolactinomas, and that such tumours are not likely to show significant tumour shrinkage with medical treatment with dopamine agonists. |
| spellingShingle | Grossman, A Ross, R Charlesworth, M Adams, C Wass, J Doniach, I Besser, G The effect of dopamine agonist therapy on large functionless pituitary tumours. |
| title | The effect of dopamine agonist therapy on large functionless pituitary tumours. |
| title_full | The effect of dopamine agonist therapy on large functionless pituitary tumours. |
| title_fullStr | The effect of dopamine agonist therapy on large functionless pituitary tumours. |
| title_full_unstemmed | The effect of dopamine agonist therapy on large functionless pituitary tumours. |
| title_short | The effect of dopamine agonist therapy on large functionless pituitary tumours. |
| title_sort | effect of dopamine agonist therapy on large functionless pituitary tumours |
| work_keys_str_mv | AT grossmana theeffectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT rossr theeffectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT charlesworthm theeffectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT adamsc theeffectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT wassj theeffectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT doniachi theeffectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT besserg theeffectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT grossmana effectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT rossr effectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT charlesworthm effectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT adamsc effectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT wassj effectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT doniachi effectofdopamineagonisttherapyonlargefunctionlesspituitarytumours AT besserg effectofdopamineagonisttherapyonlargefunctionlesspituitarytumours |